Bio-Techne (FRA:TE1) Total Receivables: €186 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TE1 Bio-Techne Corp FRA:TE1
85 GF Score
Price €62.36
GF Value €62.81
! 8 Warning Signs
View Full Analysis

What is Bio-Techne Total Receivables?

Bio-Techne FRA:TE1 +1.04% 85 Total Receivables is €186 Mil as of Mar. 2026. GuruFocus rates FRA:TE1 with a GF Score™ of 85/100 and a GF Value™ of €62.81. The stock has 8 warning signs investors should review.

Bio-Techne's Total Receivables for the quarter that ended in Mar. 2026 was €186 Mil.

Bio-Techne Total Receivables Historical Data

* Premium members only.

The historical data trend for Bio-Techne's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Techne Total Receivables Chart

Bio-Techne Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 120.67 184.04 201.65 224.26 179.36

Bio-Techne Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 219.35 179.36 156.68 157.66 185.60
FRA:TE1
85GF Score
Bio-Techne Corp FRA:TE1
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Techne Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €186 Mil mean?
Bio-Techne (FRA:TE1) has a Total Receivables of €186 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Bio-Techne and its competitors.
Is Bio-Techne's Total Receivables too high?
Bio-Techne's current Total Receivables is €186 Mil. Overall, Bio-Techne has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Total Receivables compare to ARWR and CYTK?
Bio-Techne's Total Receivables of €186 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Bio-Techne and its competitors. Bio-Techne's current Total Receivables is €186 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Bio-Techne (FRA:TE1) has a current Total Receivables of €186 Mil. The stock's GF Value™ is €62.81, compared to a current price of €62.36 — trading 0.7% below its estimated fair value. The current Total Receivables is €186 Mil. Bio-Techne's overall GF Score™ is 85/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Bio-Techne (FRA:TE1), the current Total Receivables is €186 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Techne (FRA:TE1) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued. The current stock price of €62.36 is trading 0.7% below its estimated GF Value™ of €62.81.

Key valuation signals for FRA:TE1:

  • Total Receivables: €186 Mil
  • GF Value™: €62.81 vs. price of €62.36 (0.7% below fair value)
  • GF Score™: 85/100 with 8 warning signs

No single metric tells the full story. See the FRA:TE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Techne Business Description

Address 614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
85GF Score

Get the complete analysis for FRA:TE1

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€62.36
Price
€62.81
GF Value